Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 1 , Pages 17-40, February 2008

Neonatal hyperglycaemia and abnormal development of the pancreas

  • Hélène Cavé, Dpharm, PhD (Biochemist Involved in the Diagnosis of Genetic Disorders)
  • Michel Polak, MD, PhD (Pediatric Endocrinologist, Professor)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +33 1 44 49 48 02; Fax: +33 1 44 38 16 48.

Clinique des Maladies du Développement, Unité d'Endocrinologie, Diabétologie et Gynécologie Pédiatrique, Hôpital Necker-Enfants Malades, Paris, France

Centre National de la Recherche Scientifique UMR 8090, Institute of Biology and Pasteur Institute, Lille, France

Genetic biochemistry, Hôpital Robert Debré, Paris, France

Unité INSERM U845, University Paris V, Paris, France

Genetic biochemistry, Hôpital Robert Debré, Paris, France

Imperial College, Hammersmith Hospital (PF), London, UK

Clinique des Maladies du Développement, Unité d'Endocrinologie, Diabétologie et Gynécologie Pédiatrique, Hôpital Necker-Enfants Malades, 149 rue de Sèvres, Paris, France Unité INSERM U845, University Paris V, Paris, France

Transient and permanent neonatal diabetes mellitus (TNDM and PNDM) are rare conditions occurring in around 1 per 300,000 live births. In TNDM, growth-retarded infants develop diabetes in the first few weeks of life, only to go into remission after a few months with possible relapse to permanent diabetes usually around adolescence or in adulthood. In PNDM, insulin secretory failure occurs in the late fetal or early postnatal period. The very recently elucidated mutations in KCNJ11 and ABCC8 genes, encoding the Kir6.2 and SUR1 subunits of the pancreatic KATP channel involved in regulation of insulin secretion, account for a third to a half of the PNDM cases. Molecular analysis of chromosome 6 anomalies and the KCNJ11 and ABCC8 genes encoding Kir6.2 and SUR1 provides a tool for distinguishing transient from permanent neonatal diabetes mellitus in the neonatal period. Some patients (those with mutations in KCNJ11 and ABCC8) may be transferred from insulin therapy to sulphonylureas.

Key words: neonatal diabetes mellitus, pancreatic insufficiency, β-cell function, insulin secretion, insulin therapy, newborns, genetic mechanisms, imprinting, diabetes mellitus genes, potassium channel, SUR1, kir6.2

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1521-690X(07)00080-2

doi:10.1016/j.beem.2007.08.003

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 1 , Pages 17-40, February 2008